Mersana Therapeutics (NYSE: MRSN) — Perfil da empresa, notícias e dados financeiros
Mersana Therapeutics develops antibody-drug conjugates for cancer treatment, focusing on improving patient outcomes.
Mersana Therapeutics
Mersana Therapeutics (NASDAQ:MRSN) is a biotechnology firm focused on developing transformative antibody-drug conjugates (ADCs) for treating various forms of cancer. Specializing in leveraging its proprietary platform to create drug conjugates that aim to improve outcomes for cancer patients, Mersana's operations span from drug discovery through clinical trials. The company's projects include a pipeline of novel ADCs targeting both solid tumors and hematological malignancies, with multiple drugs currently undergoing clinical evaluation. Mersana's objectives revolve around advancing its research and development efforts to bring innovative cancer therapies to market, ultimately improving patient care and expanding treatment options for oncologists and their patients. Through rigorous scientific research and clinical development, Mersana seeks to make a significant impact in oncology.
Resumo
Operações
Produtos e/ou serviços de Mersana Therapeutics
- Upifitamab rilsodotin (UpRi) is a novel antibody-drug conjugate targeting NaPi2b-expressing tumors for ovarian and lung cancer.
- XMT-1660, a Dolasynthen-based B7-H4-targeted ADC, is aimed at treating solid tumors with high unmet needs.
- XMT-2056, an Immunosynthen-based ADC, focuses on innovatively treating cancer through immune stimulation.
- XMT-1536, another NaPi2b-targeted ADC, offers therapeutic potential for patients with ovarian and lung cancer but with a different payload.
- Partnered with Merck, they are exploring the combination of UpRi with pembrolizumab for treating ovarian cancer, leveraging Merck's expertise in immunotherapy.
- Their proprietary Dolasynthen and Immunosynthen platforms enable the development of highly potent and targeted ADCs for multiple cancer types.
equipe executiva do Mersana Therapeutics
- Dr. Martin H. Huber M.D.President, CEO & Director
- Mr. Brian C. DeSchuytnerSenior VP, CFO & COO
- Dr. Timothy B. Lowinger Ph.D.Senior VP and Chief Science & Technology Officer
- Ms. Alejandra Veronica Carvajal J.D.Senior VP, Secretary & Chief Legal Officer
- Dr. Mohan Bala Ph.D.Senior VP & Chief Development Officer
- Mr. Mikhail Papisov Ph.D.Co-Founder
- Mr. Ashish MandeliaVP & Chief Accounting Officer
- Mr. Chuck MillerSenior Vice President of Regulatory Affairs
Principais indicadores financeiros
Resultados divulgados pela Mersana Therapeutics, em USD.
| Fim do ano fiscal | Receita | Resultado operacional | Lucro líquido |
|---|---|---|---|
| 40,5 mi | -73,3 mi | -69,2 mi | |
| 36,9 mi | -171 mi | -171,7 mi | |
| 26,6 mi | -203,8 mi | -204,2 mi | |
| 43 mil | -168,9 mi | -170,1 mi |